Loading
NASDAQHealthcareDrug Manufacturers - General
Latest quote
$3.02
−$0.47 · -13.47%
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Regular session
$3.02
−$0.47 · -13.47%
Regular session · ET · Market data may be delayed.
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Day range
Current $3.02
52-week range
Current $3.02
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
38
Expensive
Sentiment
55
Mixed
Risk
75
High Risk
Momentum
51
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Day range
Current $3.02
52-week range
Current $3.02
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 30.25M USD | 56.59M USD | 46.74M USD | 38.03M USD | 31.32M USD |
| Cost of goods sold | 15.22M USD | 16.69M USD | 15.68M USD | 10.8M USD | 3.63M USD |
| Gross profit | 15.03M USD | 39.9M USD | 31.06M USD | 27.24M USD | 27.68M USD |
| Research and development | 20.71M USD | 9.64M USD | 12.75M USD | 9.05M USD | 9.2M USD |
| Selling, general, and administrative | 266.63M USD | 119.02M USD | 119.64M USD | 64.9M USD | 50.58M USD |
| Operating expenses | 287.34M USD | 123.3M USD | 136.49M USD | 77.87M USD | 63.52M USD |
| Interest expense | 11.46M USD | 1.96M USD | 1.07M USD | 9.6M USD | 11.76M USD |
| Depreciation and amortization | 4.62M USD | 4.05M USD | 4.15M USD | 3.96M USD | 3.78M USD |
| Operating income | −272.3M USD | −83.4M USD | −105.43M USD | −50.63M USD | −35.84M USD |
| Net income | −358.73M USD | −72.81M USD | −114.33M USD | −23.36M USD | −88.42M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 15, 2025 | 1:35 | — | — |
Effective Apr 15, 2025
1:35
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.2M0.00%2.3T USD0.03%$379.1-0.51%
Vanguard Extended Market ETFVXF418.88K0.00%95.4B USD0.05%$232.66-0.36%
iShares Micro-Cap ETFIWC83.53K0.01%1.33B USD0.60%$182.16-0.65%
Avantis Total Equity Markets ETF 1AVTM279.2—793.48M USD0.23%$55.21-0.61%
Dimensional - US Core Equity Market ETFDFAU230.340.00%13.06B USD0.12%$53.085-0.42%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAvantis Total Equity Markets ETF 1AVTMDimensional - US Core Equity Market ETFDFAUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
